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Abstract: The number of thyroid cancers is increasing. Standard treatment usually includes 
primary surgery, thyroid-stimulating hormone suppressive therapy, and ablation of the thyroid 
remnant with radioactive iodine (RAI). Despite the generally good prognosis of thyroid 
carcinoma, about 5% of patients will develop metastatic disease, which fails to respond to RAI, 
exhibiting a more aggressive behavior. The lack of specific, effective and well-tolerated drugs, 
the scarcity of data about the association of multi-targeting drugs, and the limited role of 
radioiodine for dedifferentiated thyroid cancer, call for further efforts in the field of new 
drugs development. Rearranged during transfection (RET)/papillary thyroid carcinoma gene 
rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, 
RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis 
pathways are some of the known pathways playing a crucial role in the development of 
thyroid cancer. Targeted novel compounds have been demonstrated to induce clinical 
responses and stabilization of disease. Sorafenib has been approved for differentiated thyroid 
cancer refractory to RAI. 
OPEN ACCESS
Int. J. Mol. Sci. 2015, 16 6154 
 
 
Keywords: dedifferentiated thyroid cancer; radioiodine; papillary thyroid carcinoma;  
RET (REarranged during Transfection); BRAF (B-Raf proto-oncogene, serine/threonine 
kinase); RAS (Rat Sarcoma); vascular endothelial growth factor receptor 2; vandetanib;  
cabozantinib; sorafenib 
 
1. Introduction 
Thyroid cancer is the most common endocrine malignancy, causing approximately 1%–5% of all 
cancers in females and less than 2% in males [1,2]. 
New risk factors have emerged in the last decade [3]. 
Differentiated thyroid carcinomas (DTC), more than 90% of all thyroid tumors, arise from follicular 
cells, and are classified as papillary (PTC) or follicular (FTC) according to histopathological criteria [2]. 
In the last decades, an increasing incidence of thyroid cancer (TC) has been reported, in particular  
for PTC [1]. DTC therapy options are near-total or total thyroidectomy and lymph nodes dissection  
(in the case lymph nodes are thought to be involved). If the tumor stage of the patients (pts) leads to 
suppose a significant risk of recurrence or disease-related mortality, subsequent radioiodine ablation is 
recommended [4]. Thyroid-stimulating hormone (TSH) suppressive therapy is undertaken and annual 
follow-up based on neck ultrasonography and serum thyroglobulin (Tg) determination are performed [5–7]. 
In pts with no clinically evident residual tumor and with undetectable serum Tg level and negative 
neck ultrasonography, diagnostic whole-body radioactive iodine (RAI) scan is usually not necessary [4]. 
DTC show a good prognosis, as more than 85% pts has normal life expectancy [8]. 
Five percent of pts show distant metastasis at the diagnosis (50% lungs, 25% bones, 20% lungs and 
bones, 5% other sites). During the follow-up, 10%–15% of pts present recurrent disease (localized in  
the thyroid bed and lymph nodes), and show a reduction of survival (from 68% to 49% at 10-year);  
about one third of cancer-related deaths are associated with the presence of neck lesions alone [9]. 
As the tumor progresses and tumor cells lose the iodide uptake ability, cancer becomes resistant to 
the traditional therapeutic strategies, and the prognosis worsens significantly [10]. 
From a histopathological point of view, poorly differentiated thyroid carcinomas (PDTCs) are  
a subset of thyroid tumors intermediate between DTC and anaplastic thyroid cancers (ATC);  
Poorly differentiated thyroid carcinomas are more aggressive than DTC, but less than ATC [11,12]. 
Various molecular changes within PTC cells, such as RET/PTC rearrangements, RAS and BRAF 
mutations [13], β-catenin mutations [14] underlie the loss of iodide uptake ability. 
The aim of this review is to evaluate the state of art of targeted therapies in the approach of dedifferentiated 
papillary thyroid cancer (DePTC). 
2. Molecular Pathways Involved in DePTC 
2.1. RET/PTC Rearrangements, BRAF, RAS, PAX8/PPARγ, Histone Acetylation 
RET (REarranged during Transfection), that is involved in cell differentiation, migration and 
proliferation, is a proto-oncogene located on 10q11.2, and encodes a transmembrane protein whose 
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intracellular region harbors a tyrosine kinase (Figure 1). Activating RET mutations and rearrangements 
have been found in various human cancer and cancer syndromes [15–17]. 
In particular, an erroneous reparative fusion of the C-terminal kinase domain of RET and N-terminal 
domain of an unrelated gene, close to RET, causes RET rearrangements. The resultant chimeric protein 
dimerizes and autophosphorilates the tyrosine residues of RET. This causes the constitutively activation 
of the chimeric protein, resulting in an uncontrolled proliferation [18]. 
For instance, RET/PTC rearrangements are found in up to 40% of adult sporadic PTC [16]. 
The most frequent rearrangements, RET/PTC (RET gene rearrangements in papillary thyroid 
carcinomas) (given by the fusion with the CCDC6 gene, formerly H4) and RET/PTC3 (given by the 
fusion with the NCOA4 gene, formerly ELE1) [19] induce thyroid tumors characterized by nuclear 
grooves and ground glass cells, continuous slow growth rate, and loss of iodide uptake, in transgenic 
mice similarly to human PTC [20]. 
Several studies show that thyroid cells exposed to ionizing radiations develops RET/PTC rearrangements, 
particularly RET/PTC3 [21]. 
This rearrangement is also associated with the solid variant, a more aggressive phenotype, a greater 
tumor size, and a more advanced stage at diagnosis, which are all poor prognostic factors [22]. 
Many authors hypothesize that RET/PTC rearrangements are important for the initiation of the tumor, 
but are not necessary for its further progression, as RET/PTC rearrangements are frequently found in 
microcarcinomas, in thyroid adenomas and non neoplastic lesions [23]. 
BRAF, a member of the RAF family proteins, is a serine-threonine kinase that, upon binding to RAS, 
phosphorilates MEK (mitogen-activated protein kinase kinase) activating the MAPK (mitogen-activated 
protein kinases) cascade (Figure 1). Valine to glutamate substitution at residue 600 (V600E) is found in 
about 45% PTC and rarely in FTC and is correlated with the tumor aggressiveness at presentation, with 
the risk of tumor recurrence, and with the loss of iodide uptake [18,24]. 
RAS (“Rat Sarcoma”) is the name given to a gene family, constituted by K-RAS, N-RAS and  
H-RAS. These genes encode intracellular G-proteins involved in activation of several signaling  
pathways (Figure 1) [25]. 
The translocation of the DNA binding domain of PAX8 (Paired box gene 8) to domains A–F of the 
peroxisome proliferator-activated receptor (PPAR)γ1 gene is found in 30%–40% of FTC and in 2%–10% 
of follicular adenomas [26,27]. PAX8/PPARγ rearrangements are less common in the follicular variant 
of PTC, and rarely are found in the other variants of PTC (0%–1%) [27]. 
The mechanism of acetylation of NH2-terminal lysine residues on histones enhances gene 
transcription switching chromatin in a more open configuration. When histones are hypoacetylated, 
chromatin maintains a closed configuration, which hinders gene transcription [28]. 
2.2. Factors Involved in Angiogenesis 
By measuring microvascular density, differences in angiogenesis have been related to differences in 
tumor behavior. Thyroid tumors are more vascular than normal thyroid tissue, and there is a clear correlation 
between increased angiogenesis and a more aggressive thyroid tumor behavior and metastasis [29]. 
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Experimental evidence has shown that thyroid neoplastic growth and subsequent metastasis formation 
depend on the tumor’s ability to induce an angiogenic switch, induced by a change in the balance of 
angiogenic stimulators and inhibitors [30,31]. 
Some of these are VEGF (vascular endothelial growth factor)/VEGF receptors, EGF (epidermal 
growth factor)/EGF receptors, PDGF (platelet-derived growth-factor)/PDGF receptors, FGF (fibroblast 
growth factor)/FGF receptors, HGF (hepatocyte growth factor)/c-Met, and the downstream signaling 
through Ras-Raf-ERK, Ras-PI3K-AKT-mTOR (Figure 1). Growth factors receptor and the downstream 
molecules mostly are protein kinases that act by phosphorylation [32]. 
In the classic model by Hanahan and Weinberg, the molecules are constitutively activated by mutations, 
rearrangements or amplifications, so that tumor growth is independent from the external growth factors [33]. 
2.2.1. Vascular Endothelial Growth Factor (VEGF) 
VEGF gene family includes VEGF A–C, placental growth factor (PlGF) and PDGF A–D [34]. VEGF 
is able to mediate endothelial cell adhesion and migration on extracellular matrix, and for this reason  
is associated with an increased aggressiveness, growth and distant spread of several tumors, including 
TC [35,36]. 
VEGF is overexpressed and its main receptor VEGFR-2 is up-regulated in many DTC [28]. 
In TCs a consistent increase in VEGF, VEGF-C, and angiopoietin-2 was observed. The overexpression 
of angiopoietin-2 and VEGF was shown in thyroid tumor progression, such as a strong association between 
tumor size and high levels of VEGF and angiopoietin-2. It has been also shown an increased expression 
of VEGF-C in lymph node invasive thyroid tumors and, on the other hand, a decrease of thrombospondin-1, 
an angioinhibitory factor, in thyroid malignancies capable of hematic spread. These results suggest  
that, in human thyroid tumors, angiogenesis factors are involved in neoplastic growth, progression and 
aggressiveness [30]. 
Systemic administration of antiangiogenic drugs that target components of the VEGF-A-VEGF signal 
transduction pathway (Figure 1) has become a therapeutic option for patients with TC [37]. 
2.2.2. EGF Receptor (EGFR) 
Similarly to VEGF, EGFR (ErbB-1; HER1 in humans) plays a role in TC growth and spread, so  
that it is highly expressed in aggressive TC (Figure 1). EGFR mutations contribute to RET activation  
in thyroid cancer [38,39]. In turn, RET/PTC1 and RET/PTC3 up-regulate EGFR expression, with  
a magnitude of induction similar to that for TSH [38]. 
The expression of EGFR1 protein is significantly up-regulated in poorly differentiated and ATCs, 
whereas it is absent or faint in normal thyroid gland tissue and in differentiated thyroid papillary carcinomas, 
suggesting that up-regulation of EGFR1 expression may be a molecular marker of dedifferentiation in 
thyroid epithelial carcinomas [40]. 
High expression of EGFR is associated with lymph node metastasis in PTC, and plays a role in  
the progression of TC [41–43]. 
More recently, it has been reported a patient with metastatic poorly differentiated thyroid carcinoma 
with an EGFR mutation who responded to treatment with the selective EGFR TKI (tyrosine kinase 
inhibitor) erlotinib, strongly suggesting the importance of EGFR as therapeutic target in DePTC [44]. 
Int. J. Mol. Sci. 2015, 16 6157 
 
 
 
Figure 1. Molecular targets and tyrosine kinase inhibitors in the signaling pathways involved 
in dedifferentiated papillary thyroid cancer. 
2.3. Genomic Analysis 
It has been recently described the genomic landscape of 496 PTCs. A low frequency of somatic 
alterations was observed and it was extended the set of known PTC driver alterations to include EIF1AX, 
PPM1D, and CHEK2 and some gene fusions. The fraction of PTC cases with unknown oncogenic driver 
was reduced from 25% to 3.5%. Combining the results of the analyses of genomic variants, with gene 
expression, and methylation it was demonstrated that different driver groups lead to different pathologies 
with specific differentiation characteristics. It was also proposed a reclassification of TCs into molecular 
subtypes that better reflect their underlying signaling and differentiation properties. This reclassification 
could improve the pathological classification of PTC, helping the management of the disease [45]. 
2.4. Tyrosine Kinase Inhibitors (TKIs) 
Many strategies have been carried out to block TKI. As RNA interference is difficult to implement, 
TKI blockade is achieved through monoclonal antibodies against growth factors receptors or TKIs, 
which act by interfering with the kinase domain-ATP interaction or as allosteric inhibitors [32]. 
TKIs are emerging as potentially effective options in the treatment of advanced TC. As TKIs are  
not specific for one kind of tyrosine kinase, we refer to them as multikinase inhibitors. They mostly act 
on the abovementioned pathways, which, in turn, are involved in angiogenesis, growth, invasiveness, 
avoidance of apoptosis, and both local and distant spread [46]. 
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Given the fact that TKIs act on pathways that are not selective for a specific malignancy, they have 
been tested on several tumors, including DTC, medullary thyroid cancer (MTC) and ATC [47]. 
Individual patient responses are assessed by the response evaluation criteria in solid tumors (RECIST) 
in the clinical trials evaluating TKIs [48]. 
Since stable disease in the absence of active treatment is not uncommon, an essential component of 
the RECIST is that the selection criteria for clinical trials have to include patients who demonstrate 
measurable disease progression about within 6 months before enrollment. RECIST requires that enrolled 
patients have measurable target lesions > 2 cm in the largest diameter using conventional imaging techniques 
or > 1 cm using spiral computed tomography scan, up to a maximum of 5 lesions per organ and  
10 lesions in total. Then, the response is analyzed using this baseline evaluation, but it precludes  
the enrollment of some thyroid cancer patients who do not meet such stringent criteria but may still 
benefit from targeted therapy [49]. 
Therefore, a “rapidly progressive disease” has been defined as one showing a >30% tumor growth 
progression within 12 months. 
3. Sorafenib 
Sorafenib (BAY 43-9006) is a multikinase inhibitor, with a potent activity against RAF, VEGF receptors 
(VEGFR-2, VEGFR-3), PDGF receptor (PDGFR), c-KIT and RET kinases [50,51]. 
In preclinical studies, sorafenib has been shown a broad-spectrum antitumor activity in several cancer 
xenograft models, as colon, breast and non-small-cell lung cancer [50]. Carlomagno et al. [52] published 
a paper on inhibition of oncogenic RET mutants by sorafenib in 2006, showing as the TKI prevented the 
growth of the TPC1 and TT cell lines, TC cell lines that contain the RET/PTC1 and C634W RET mutation, 
respectively. This drug, therefore, potentially may inhibit TC growth both through anti-proliferative and 
anti-angiogenic mechanisms [53]. 
Sorafenib, actually approved by Food and Drug Administration (FDA) for hepatocellular and renal 
cell carcinoma, is orally administered at a maximum dose of 400 mg twice daily, and generally is well 
tolerated. The most frequently reported drug-related adverse events (AE) at any grade included fatigue, 
anorexia, diarrhea, rash/desquamation and hand–foot syndrome [54]. Given the encouraging results from 
in vitro and in vivo trials and the necessity to develop new therapies for iodine-refractory metastatic TC, 
new studies have been initiated (Table 1). 
A phase II trial [55], evaluated the efficacy of sorafenib in 30 pts with metastatic, iodine-nonavid, 
TC, including differentiated, poorly differentiated, medullary, and anaplastic subtypes. The drug was 
administrated at 400 mg bid/die; the median duration of treatment was 27 weeks. Six pts (20%) discontinued 
treatment as a result of AE. Doses were reduced in 47% of pts (14 pts) to control toxicities. A partial 
response (PR) rate was observed in 23.3% and a stable disease (SD) rate in 53.3%, obtaining a clinical 
benefit rate (PR plus SD) of 77%, with a median progression-free survival (PFS) of 21 months in pts 
with DTC. The rate of AE is consistent with other sorafenib trials [55].  
A few months later, a study was published of 58 pts with metastatic TC, divided in two parts [56].  
In the first part, 25 pts were enrolled with metastatic PTC and chemotherapy naive; in the second, 
patients with PTC, but previously treated with chemoterapy, and other subtype (follicular, Hurthle cell, 
anaplastic, or mixed thyroid carcinoma) were enrolled. Activating mutations in exon 15 of BRAF was 
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found in 17 of 22 pts with PTC examined. Sorafenib was administrated at 800 mg daily, in two doses, 
generally well tolerated. This trial showed that sorafenib has clinical and biologic antitumor activity in 
metastatic PTC, obtaining a PR in 6 pts, while 23 pts had SD longer than 6 months. However, the role 
of BRAF has not been elucidated definitively [56]. An open-label phase II study of sorafenib at  
maximum dose (800 mg daily) in metastatic iodine-refractory TC was conducted by Brose et al., in 55 pts  
with different histological subtypes (47% PTC, 36% FTC/Hürthle Cell, 8% MTC, 9% poorly 
differentiated/anaplastic) [57]. Genotyping of BRAF was complete in 16 pts. The preliminary results 
presented at 2009 ASCO annual meeting evidenced an increased PFS in pts with PTC/FTC with  
B-RafV600E compared to wild-type B-Raf (84 vs. 54 weeks, p = 0.028). Also, heterogeneity of expression 
of p-ERK and p-AKT was demonstrated in different tissue areas on treatment [57]. 
The ability of sorafenib to reinduce RAI uptake in pts with progressive metastatic or locally advanced 
RAI refractory DTC was evaluated in a prospective phase II study [58]. During 26 weeks, 31 pts received 
sorafenib 400 mg twice daily. It was observed 59% of clinical beneficial response, 25% of PR and 34% 
of SD, the estimated PFS was 58 weeks. However, 22% of pts had progressive disease (PD) and diagnostic 
body scan did not reveal any reinduction of RAI uptake. Sorafenib results were clearly less effective in 
pts with bone metastases [58]. 
A paper published in 2010 reports the M. D. Anderson Cancer Center’s experience with the off-label 
use of the TKIs sorafenib and sunitinib for refractory to iodine DTC (papillary and follicular thyroid 
cancer) [59]. Sorafenib was used in 13 pts, at the same dose of previous trials described. The results 
obtained are comparable to other phase II studies evaluating sorafenib in TC (remission rate of 20%, 
durable response rate of 66%, and a clinical benefit rate of 80%). A longer PFS (19 months) and  
the median overall survival at 2 years was 67%. In this study, a response variability of the different 
metastases in the same patient to same therapy was found, with best response in lung and minimal  
in nonirradiated bone lesions, suggesting a differential expressions and inhibitions of various receptors. 
Moreover, it has also been evidenced a reduction of Tg levels preceding tumor shrinkage and  
a correlation between the log Tg and the response to treatment after the start of therapy, suggesting that 
Tg would be a reliable biologic marker of response to treatment. These data should be validated in larger 
studies [59]. 
In another phase II study, sorafenib was administered at 400 mg twice daily in 15 pts with metastatic 
MTC and 19 pts with locally advanced RAI refractory DTC [60]. The radiological response rate (RR) 
was 18% for pts with DTC, while the PFS at 2 years was 62% and overall survival 72%. However, 79% 
of pts required dose reduction for AE (hand–foot syndrome, other skin toxicities, diarrhoea and alopecia).  
A mutation in BRAF exon 15 was detected in one patient who had demonstrated a dramatic response 
after 3 months of therapy. Anyway, the sequencing was performed on 10 DTC pts and results were obtained 
on only 3 of these [60]. 
In the 2011 ASCO annual meeting the results of UPCC 03305 phase II trial of sorafenib for advanced 
thyroid carcinoma was presented. Fifty-five pts (85% DTC/PDTCs, 9% ATC, 6% MTC) received  
the drug at same dose provided in the preceding studies. A longer PFS was observed in pts with 
DTC/PDTCs (96 vs. 93.6 weeks of other thyroid cancer), 38% achieved a PR, 47% had SD. In 66% 
tissue from patient with DTC/PDTCs was found at least 1 mutation (45% BRAF, 19% RAS, 11% RET, 
9% PIK3CA), while in 17% multiple mutation (60% in ATC) [61]. 
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In 2012, data from a retrospective, longitudinal study on use of sorafenib in pts with progressive  
RAI-refractory DTC was published [62]. Sorafenib has been used off-label in 17 pts, independently from 
their performance status, at conventional dose. Although the drug was tolerated, 5 fatal events was reported 
(3 severe bleeding and 2 cardiac arrest), all pts needed dose reductions and/or transient drug interruption 
to control AE. Thirty percent of pts achieved PR, 41% SD and 18% PD, median PFS was 9 months and 
median overall survival 10 months. These results probably depended on the general pts conditions at  
the beginning of the trial, which were worse than other studies. The RR was greater in lymph nodes than 
lung metastasis, baseline fluorodeoxyglucose-positron emission tomography (FDG-PET) assessment 
and early FDG-PET response were correlated to radiological response. The FDG-PET could be helpful 
for the timely identification of non-responding pts, in fact an early reduction in average standardized 
uptake value was recorded in all pts, but was greater in responding subjects [62]. 
To evaluate the efficacy of sorafenib in pts with advanced RAI refractory DTC, another phase II trial 
was conducted on 31 pts receiving sorafenib at 800 mg (400 mg twice daily); the median follow-up and 
period of treatment was 25 and 9 months, respectively [63]. BRAF V600E was the most observed mutation 
among the ones evidenced, but not related to disease progression. PR was obtained in 31% and 42% 
achieved SD after a median follow-up of 25 months. The dose of TKI used was generally well tolerated, 
although dose reductions were required in 58% of pts, most frequent AE was dermatological [63]. 
Table 1. Clinical trials of Sorafenib in patients with thyroid cancer. 
Drug 
Thyroid 
Cancer 
Responses 
Authors 
PR SD PD 
PFS 
(months) 
Sorafenib 30 DeTC 23.3% 53.3% 7% 21 Gupta-Abramson et al. [55] 
Sorafenib 41 DeTC 15% 56% – 15 Kloos et al. [56] 
Sorafenib 31 DeTC 25% 34% 22% 14.5 Hoftijzer et al. [58] 
Sorafenib 13 DeTC 20% 60% 20% 19 Cabanillas et al. [59] 
Sorafenib 
19 DeTC  
15 MTC 
18% DeTC 
25% MTC 
– – – Ahmed et al. [60] 
Sorafenib 
47 DeTC  
5 ATC  
3 MTC 
38% DeTC 
47% 
DeTC 
– 23.4 Keefe et al. [61] 
Sorafenib 17 DeTC 30% 41% 18% 9 Marotta et al. [62] 
Sorafenib 31 DeTC 31% 42% – 18 Schneider et al. [63] 
Sorafenib 207 DeTC – – – 10.8 Brose et al. [64] 
Sorafenib 8 DeTC 12.5% 62.5% 25% 14–24 Pitoia [65] 
Sorafenib  
Sunitinib  
Vandetanib 
32 DeTC  
13 ATC  
17 MTC 
15% vs. 8% 
DeTC  
36% MTC 
– – 
6.7 vs. 7 
DeTC 
Massicotte et al. [66] 
Anaplastic thyroid cancer (ATC); dedifferentiated thyroid cancer (DeTC); medullary thyroid cancer (MTC); 
partial response (PR); progressive disease (PD); progression-free survival (PFS); stable disease (SD). 
A randomized, double-blind, placebo-controlled, phase III trial (DECISION), investigated sorafenib 
(400 mg orally twice daily) in pts with RAI-refractory locally advanced or metastatic DTC that had 
progressed [64]. The intention-to-treat population included 417 pts (207 in the sorafenib group and  
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210 in the placebo group) and the safety population was 416 pts (209 pts instead of 210 in  
the placebo group). Median PFS was higher in the sorafenib group (10.8 months) than in the placebo 
group (5.8 months) and improved in all clinical and genetic biomarker subgroups, irrespective of mutation 
status. AE occurred in 98.6% pts receiving sorafenib: the most frequent were hand-foot skin reaction 
(76.3%), diarrhoea (68.6%), alopecia (67.1%), and rash or desquamation (50.2%). These results suggest 
that sorafenib is an effective treatment for pts with RAI-refractory DTC [64]. 
Also, other more recently published studies suggest a possible role for sorafenib in the treatment of 
progressive metastatic DTC [65,66]. 
4. Sunitinib 
Sunitinib (SU011248) is a small molecule, multitargeted TKI, acting as a selective inhibitor of 
VEGFR-1, 2, and 3, PDGFR, cKIT, and RET/PTC subtypes 1 and 3, that are involved in signal transduction 
and growth and their inhibition is determinant in the development of solid tumors [67,68]. Sunitinib is 
orally administered and is approved for the therapy of clear-cell renal carcinoma and gastrointestinal 
stromal tumor (GIST) on an intermittent treatment schedule [69], but is under investigation also in other 
human malignancies. The most common drug-related AE described are fatigue, diarrhea, palmar-plantar 
erythrodysesthesia, neutropenia, hypothyroidism and hypertension [70]. 
The antitumoral properties of sunitinib have been investigated by various preclinical studies  
(Table 2) and Kim et al. showed that is a potent inhibitor of RET/PTC oncoproteins in vitro [71]. 
Sunitinib decreases RET/PTC autophosphorylation and STAT3 (signal transducer and activator of 
transcription) activation, and blocks the transforming capacity of RET/PTC. Furthermore, it exerted  
a powerful growth-inhibitory effect on the TPC1 cell line, that spontaneously harbors an RET/PTC 
rearrangement [71]. 
A study has been performed to investigate the effects of sunitinib in RET/PTC1 rearrangement cells, 
focusing on signal transduction pathways and gene expression of iodide metabolizing proteins.  
An increase in sodium-iodide symporter (NIS) gene expression has been demonstrated through  
the inhibition of MEK/ERK and SAPK/JNK cytoplasmic pathways, individually and in combination, 
suggesting that blocking these pathways is the mechanism by which sunitinib exerts its direct 
antiproliferative effect [72]. 
In another preclinical study the authors investigated the different mechanism of inhibitory effects of 
sunitinib against RET/PTC rearrangement and BRAF mutation in cell lines and orthotopic TC mouse 
model [73]. Sunitinib inhibited RET/PTC but not BRAF mutated cells, suggesting that clinical application 
of sunitinib should be directed by genotyping [73]. 
The preliminary results of different phase II studies were presented in the ASCO annual meeting  
in 2008 [74]. In the first trial, 43 pts with evidence of progression of disease (37 DTC, 6 MTC) received 
sunitinib 50 mg daily on a 4-week-on/2-week-off schedule. Thirty-one pts with DTC completed 2 cycles 
for evaluation: PR was 13%, SD 68%. For MTC the best response was SD, at 83% [74]. 
In the second trial, Goulart et al. [75] enrolled 18 subjects with metastatic, RAI-refractory and 
evidence of FDG-PET avid TC (3 MTC, 15 DTC). Sunitinib was administrated at 37.5 mg daily and  
FDG-PET was performed in 16 pts at baseline and after 7 days of treatment. The FDG-PET response 
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rate was observed in 7 pts, all of them with DTC histology; the RECIST response rate was still being 
evaluated at the time of report. One patient died for gastrointestinal bleeding [75]. 
The results for first period of the THYSU study were presented [76]. Sunitinib was given at 50 mg 
daily for 4 weeks every 6 weeks. Fifteen/17 pts were enrolled (1 ATC, 4 MTC, 8 PTC and 4 other TC) 
and evaluable for response: 1 pt had a PR, 12 had SD, with 1 pt with >90% decrease of Tg and 1 pt with 
a dramatic decrease of symptoms [76]. 
The data from the largest open-label phase II trial was published in 2010 [77], conducted on 28 pts 
with progressive DTC and 7 with MTC, who received 37.5 mg of sunitinib on continuous basis. A complete 
response (CR) was observed in 3%, PR in 28% and SD in 46% of subjects. The most common toxicities 
observed included fatigue (11%), neutropenia (34%), hand/foot syndrome (17%), diarrhea (17%), and 
leukopenia (31%). Reduction in fluorodeoxyglucose uptake in positron emission tomography was  
a predictor of PR or stabilization of the disease [77]. 
Also other more recently published studies suggest a possible role for sunitinib in the treatment of 
progressive metastatic DTC [66,78]. 
Table 2. Clinical trials of Sunitinib in patients with thyroid cancer. 
Drug Thyroid Cancer 
Responses 
Authors 
PR SD PD 
PFS 
(months) 
Sunitinib 
37 DeTC  
6 MTC 
13% DeTC 
68% DeTC 
83% MTC 
10% DeTC 
17% MTC 
 Cohen et al. [74] 
Sunitinib 
12 DeTC  
1 ATC  
4 MTC 
6% 71%   Ravaud et al. [76] 
Sunitinib 
7 MTC  
28 DeTC 
28% PR + 
3% CR 
46% 17% 12.8 Carr et al. [77] 
Sunitinib 11 DeTC 
18% PR + 
9% CR 
45% 27% 11.5 Dìez et al. [78] 
Anaplastic thyroid cancer (ATC); complete response (CR); dedifferentiated thyroid cancer (DeTC); medullary 
thyroid cancer (MTC); partial response (PR); progressive disease (PD); progression-free survival (PFS); stable 
disease (SD). 
5. Imatinib 
Imatinib (STI571) is a TKI affecting several protein-tyrosine kinases: Bcr-Abl, PDGFR α e β, c-Kit 
and RET [79], approved by the USA FDA and European Medicines Agency (EMA) for the treatment of 
chronic myelogenous leukemia, and gastrointestinal stromal tumor. Imatinib has been used in several 
studies to evaluate the inhibiton of MTC, but no objective response was observed [79–81]. 
In a recent phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers, 
no responses were seen in patients with MTC, but 4 of 5 patients experienced SD [82]. 
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6. Vandetanib 
Vandetanib (ZD6474) (Table 3), is an orally active low-molecular-weight receptor TKI, potent 
inhibitor of VEGFR-2, targeting also VEGFR-3, EGFR, and RET kinases. The inhibition of RET 
oncoproteins kinase activity by ZD6474 in RET-mutant cell lines is known since 2002 [83]. 
Two single-arm phase II clinical trials were developed to evaluate the clinical utility of vandetanib in 
hereditary MTC, and reported similar preliminary results (20% of pts had a PR while an addictional 53% 
of pts experienced a SD at 24 weeks [84]; PR was achieved in 16%, SD >24 weeks in 53% [85]). 
The ZETA trial [86], an international randomized phase III trial has been performed, comparing 
ZD6474 (vandetanib 300 mg daily) and placebo in 331 MTC pts: PFS prolongation with vandetanib vs. 
placebo was observed (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; p < 0.001). 
Vandetanib was approved by FDA as the first TKI to treat adult pts with metastatic or progressive 
MTC in April 2011 [86]. 
In a double-blind phase II study [87], 145 pts with locally advanced or metastatic DTC (PTC, FTC, 
or PDTCS) improved PFS; 72 of them received vandetanib 300 mg/daily and 73 placebo. PFS was higher 
in pts treated with TKI than with placebo (11.1 and 5.9 months, respectively), PR and SD were 8% and 
57%, while for the other group they were 5% and 42%, respectively. The safety and tolerability were 
consistent with previous studies on vandetanib [87]. 
Also a more recently published study shows that vandetanib is effective in the treatment of 
progressive metastatic MTC [66]. 
Table 3. Clinical trials of Vandetanib in patients with thyroid cancer. 
Drug Thyroid Cancer 
Responses 
Authors 
PR SD PD PFS (months) 
Vandetanib 30 MTC 20% 53% 3% 27.9 Wells et al. [84] 
Vandetanib 19 MTC 16% 53% 16% 168 days Robinson et al. [85] 
Vandetanib 231 MTC 45% 42% – – Wells et al. [86] 
Vandetanib 145 DeTC 8% 57% – 11.1 Lebolleux et al. [87] 
Dedifferentiated thyroid cancer (DeTC); medullary thyroid cancer (MTC); partial response (PR); progressive 
disease (PD); progression-free survival (PFS); stable disease (SD). 
7. Motesanib Diphosphate 
Motesanib diphosphate (AMG 706) is an ATP-competitive inhibitor of VEGFR1, 2, 3, PDGFR, and 
Kit. It inhibits human endothelial cell proliferation VEGF-induced, and increases endothelial apoptosis, 
in vitro [88]. 
The first clinical trial, a phase I study with motesanib diphosphate 125 mg/day orally was conducted 
in 5 pts affected by DTC, 3 of them had a PR (i.e., >30% reduction in tumor diameters) [89]. 
Three phase II trials have been carried out in pts with advanced or metastatic, RAI-resistant TC [90–92], 
two of which in pts with MTC [90,92]. 
In all the three studies, motesanib diphosphate was administered orally 125 mg/day. This daily dose 
was confirmed to be the best dose to achieve the longest PFS [93]. 
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Sherman et al. [90] tested motesanib diphosphate on 93 DTC pts (57 pts, 61% were PTC). A PR was 
achieved in 14% of them, while SD in 35% for at least 24 weeks. Serum Tg decreased in 81% of pts compared 
to baseline. The tumor progressed in 7 pts (8%). The median PFS was 40 weeks. The most frequent AE 
were gastrointestinal (diarrhea, 59%), followed by hypertension (56%), asthenia (46%) and weight loss 
(40%). Primary hypothyroidism occurred in less than a third of pts (22%). The most common grade 3 
side effect was hypertension (25%) [90]. 
To predict the effectiveness of TKIs, various biomarkers have been identified. Bass et al. [92] treated 
184 pts (93 DTC and 91 MTC) with motesanib 125 mg/day orally for up to 48 weeks in a phase II trial; 
48% of MTC pts achieved SD for at least 24 weeks. Median PFS was 40 weeks for DTC pts, and 48 weeks 
for MTC pts [92]. Serum PlGF, antagonizing VEGF, increased, while soluble VEGFR2 decreased over 
the treatment. Both reverted toward baseline at the end of the study. Serum PlGF, soluble VEGFR2 and 
serum caspase-3/7 activity correlated with the tumor response to motesanib, while baseline serum VEGF 
correlated with a better prognosis [92]. 
8. Axitinib 
Axitinib (AG-013736) is a second-generation inhibitor of VEGFR1, 2, 3, PDGFR and c-Kit [34,94]. 
Compared to other VEGF-TKIs, it has a greater receptor specificity, particularly against VEGFR2, 
and for this reason it is the most potent available VEGFR2-TKI [95,96]. It also inhibits endothelial nitric 
oxide, protein kinase B, ERK, and induces endothelial cells apoptosis that cannot be rescued by exogenous 
VEGF [97]. 
Axitinib was more than 10-fold less potent in inhibiting PDGFR and Kit in cell-based assays, 
compared to the other VEGF-TKIs [98]. 
The maximum tolerated dose of axitinib assessed in the first phase I study was 5 mg twice daily [99]. 
In a phase II trial [100], 60 pts with advanced TC, 45 with DTC (30 PTC and 15 FTC) and 11 with MTC, 
were enrolled and administered with axitinib 5 mg twice daily. SD for at least 16 weeks was achieved 
in 39% of pts (12 PTC, 7 FTC, 3 MTC), while PR in 29% of pts (8 PTC, 6 FTC, 2 MTC). The median 
PFS was 18.1 months (72.4 weeks). A negligible effect of axitinib on KIT was confirmed, as a 32%, 35%, 
13% decrease of soluble VEGFR2, 3 and soluble Kit, respectively, was evidenced, while serum VEGF 
was 2.8-fold higher [100]. 
The most frequent toxicities were fatigue (50%), diarrhea (48%), nausea (33%), anorexia (30%) and 
a drug-responsive hypertension (28%); the last one was the most common grade 3 side effect (12%). 
Three pts had grade 4 toxicity, stroke, hypertension, and reversible posterior leukoencephalopathy, 
respectively. Eight pts (13%) withdrew axitinib because of AE [100]. 
Furthermore, axitinib did not show a cumulative dose-limiting toxicity [101]. 
To evaluate the efficacy of TKIs, various biomarkers have been proposed as surrogates, as increase 
in blood pressure [102], or in erythropoietin blood levels [103]. 
In a second phase II trial [104], the efficacy and safety of axitinib were evaluated in 52 pts with 
metastatic or unresectable, locally advanced MTC or DTC, who received a starting dose of axitinib  
5 mg twice daily. The overall objective response rate was 35% (18 PR), and 18 pts had SD for ≥16 weeks. 
The median PFS was 16.1 months, and the median overall survival was 27.2 months. Quality of life was 
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maintained during treatment with axitinib. This study suggests that axitinib could be an additional treatment 
option for pts with advanced TC [104]. 
9. Cabozantinib 
Cabozantinib (XL184), an orally multiple-receptor kinase inhibitor, inhibits VEGFR1, 2, C-MET, 
RET, c-Kit, FLT3, and Tie-2 [105]. 
Kurzrock et al. conducted a phase I trial on cabozantinib in 37 pts with MTC [106,107]: ten (29%) of 
35 MTC pts with measurable disease had a confirmed PR. 
Cabanillas et al. administered cabozantinib in 15 DTC pts with 140 mg free base (equivalent to  
175 mg salt form) daily: 8/15 (53%) had a PR, while 6/15 (40%) had a SD [108]. 
Considering the abovementioned results and the data obtained also in other studies, FDA has recently 
approved cabozantinib for the treatment of MTC [109]. 
10. Gefitinib 
Gefitinib (ZD1839) is an EGFR-inhibitor firstly used in non-small-cell lung cancer [110], that 
effectively inhibits ATC proliferation, and induces apoptosis in vitro [111]. 
Pennel et al. [112] enrolled 27 pts in a phase II trial, 18 of whom with advanced and RAI-resistant 
DTC, treated with gefitinib 250 mg/day orally. The most frequent toxicities were cutaneous (rash in 52% 
of pts) and gastro-intestinal (diarrhea in 41%, anorexia 11%, nausea 9%). The most frequent side effects 
were rash (7%) and diarrhea (4%). Although no patient achieved PR, 48% of pts attained SD at 3 months, 
while 24% and 12% at 6 and 12 months, respectively. Five/15 pts (33%) with measurable serum Tg, had 
a remarkable decrease of Tg levels (<90%) for >6 months [112]. 
The inactivation of EGFR enhances the cytotoxic effect of doxorubicin and decreases its extrusion; 
for this reason, the association of gefitinib and doxorubicin has been suggested for the treatment of metastatic 
FTC, and ATC [113]. 
Recently, a case-report on a 79-year-old male with metastatic PDTC, with an EGFR mutation, who 
responded to treatment with the selective EGFR TKI erlotinib, has been reported; a PFS of more than 
11 months has been shown [44]. 
11. Pazopanib 
As motesanib, pazopanib (GW786034) is a VEGFR1, 2, 3, PDGFR and c-Kit inhibitor, approved  
for the treatment of renal cell carcinoma [114], but, contrary to sumatinib, it does not induce apoptosis 
in human renal cell carcinoma cell lines in vitro [115]. 
Pazopanib has been evaluated in 39 pts with advanced DTC in a recent phase II trial, of whom  
37 were assessed. At the dose of 800 mg/day orally, a PR was obtained in 18 pts (49%), though no CR 
was reported; 22 pts (59%) had a PD. There were no differences between PTC and FTC. Tg decreased 
by at least 30% in 28/32 pts (88%) [116]. 
The most common toxicities were fatigue (57%), cutaneous (skin/hair hypopigmentation 59%, 
alopecia 35%), nausea (51%), diarrhea (43%), vomiting (41%), altered taste (54%), anemia (35%), 
leucopenia (30%). The most frequent grade 3 toxicities were raised ALT levels (11%), lower gastrointestinal 
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hemorrhage (8%). In 23 pts (62%) TSH serum levels raised by more than two times. The median PFS 
was 11.7 months [116]. 
More recently it was reported that combining pazopanib with microtubule inhibitors (paclitaxel) 
produced synergistic antitumor effects in ATC cells and xenografts that were associated with potentiated 
mitotic catastrophe. Pazopanib potently inhibited aurora A, with pazopanib/paclitaxel synergy recapitulated 
by aurora A short hairpin RNA knockdown or by specific aurora A pharmacological inhibition. 
Pazopanib/paclitaxel synergy was reversed by aurora A knockdown. A durable benefit resulted from 
pilot clinical translation of pazopanib/paclitaxel therapy in a patient with metastatic ATC. These results 
suggested that the pazopanib/paclitaxel combination is promising in the therapeutic approach in ATC [117]. 
12. Lenvatinib 
Levantinib (E7080) is an orally active multi-targeted TKI, which acts on VEGFR1, 2, 3, PDGFR β, 
RET, c-KIT and FGFR1, 2, 3, 4. Lenvatinib does not significantly inhibit tumor cell proliferation, but it 
exerts its action on migration and invasion [118]. 
E7080 has been demonstrated to suppress lymph node and lung metastases in a mammary tumor 
model [119]. 
Sherman et al. administered lenvatinib in 58 pts with advanced DTC 24 mg/day orally in a phase II 
trial [120]. Twenty-nine pts had a PR, while median PFS was 12.6 months. The most common AE were 
hypertension (64%), fatigue (55%) and diarrhea (45%) [120]. 
13. BRAF Inhibitors 
BRAF mutations are associated with lymph node metastases, extrathyroidal extension, tumor size, 
and multifocality in PTC [121]. BRAF activation, through TGF-β and the inhibition of Pax8, leads to 
the inhibition of NIS expression [122]. 
Dabrafenib (GSK2118436) is a potent BRAF kinase inhibitor [123], able to block in vitro the growth 
of BRAFV600E positive melanoma and colon cancer human tumor xenografts [124]. 
Falchook et al. [123] enrolled 184 pts with incurable solid tumors with Val600Glu BRAF mutation 
(Table 4), 14 of them with PTC, in a phase I trial. They took 300 mg/day of dabrafenib orally. The most 
common AE were fatigue, pyrexia, skin lesions ranging from hyperkeratosis (26%) or actinic keratosis 
(10%) through kertao acanthoma or squamous-cell carcinoma (11%—low grade, well-differentiated). 
Nine/14 pts could be assessed. Three/9 achieved PR (two confirmed) [123]. 
Vemurafenib (PLX4032), an oral analogue of PLX 4720, inhibits BRAF and is already approved  
for treatment of advanced melanoma. An ongoing phase II trial is evaluating safety and efficacy of 
vemurafenib in advanced PTC [125]. 
Other BRAF inhibitors (CEP-32496) have shown in vitro a selective action against BRAF and are 
expected to be effective and favorable also in TC [126]. 
Other drugs have been developed to interfere with the downstream RAS/RAF pathway. Most of them 
act on the mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase), whose substrates are 
ERK1/2. In vitro, MEK inhibitors inhibit growth of human tumors in mouse xenografts [127]. 
Selumetinib (AZD6244, ARRY-142886) is an oral MEK1 and MEK2 potent inhibitor tested on  
57 pts with advanced solid cancers, two of which with TC. The most common toxicities were rash (74%), 
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diarrhea (56%), nausea (44%). The 50% of maximum tolerated dose (100 mg bid) was well tolerated.  
A patient with MTC achieved SD for 19 cycles [127]. 
In another paper [128], 39 pts with iodine-refractory PTC were administered with 100 mg bid of 
selumetinib in a phase II trial. One patient (3%) experienced partial disease, while 21 (54%) achieved 
SD. Median PFS was 32 weeks (BRAF V600E > BRAF wild-type). The most frequent AE were rash, 
fatigue, diarrhea and peripheral edema [128]. 
Another MEK inhibitor, PD0325901 reduces the growth of PTC cells in vitro and in xenograft murine 
models [129]. 
Table 4. Clinical trials with BRAF inhibitors in patients with thyroid cancer. 
Drug Thyroid Cancer 
Responses 
Authors 
PR SD PD PFS (months) 
Dabrafenib 14 DeTC 21% – – – Falchook et al. [123] 
Selumetinib 2 DeTC – 100% 19 cycles – – Adjei et al. [127] 
Selumetinib 39 DeTC 3% 54% 28% 8 Hayes et al. [128] 
Dedifferentiated thyroid cancer (DeTC); partial response (PR); progressive disease (PD); progression-free 
survival (PFS); stable disease (SD). 
14. mTOR Inhibitors 
The mammalian target of rapamycin, mTOR, constituted by mTORC1 and mTORC2, is the  
main downstream effector of the PI3K/Akt pathway. It is a serine/threonine kinase that, through the 
phosphorylation of a number of proteins (p70S6 kinase, 4EBP1) regulates protein synthesis, metabolism, 
cell growth and survival [130,131]. PI3K/Akt pathway is involved in the thyroid carcinogenesis [132]. 
Indeed, the initial factor eIF4E, that binds 4EBP1, is overexpressed in PTC as well as MTC cells, and 
its levels correlate with the aggressiveness of these tumors [132]. 
The mTOR inhibitor, rapamycin, decreases TC cell growth and viability in vitro [132], and the 
activation of PI3K/Akt pathway causes the inhibition of iodide uptake by NIS. As expected, PI3K/Akt 
inhibitors increase iodide uptake. 
Everolimus (RAD001) is an orally active rapalog (rapamycin analog) that inhibits mTORC1, upon 
binding FKBP12 [133,134]. It has been approved by FDA for the treatment of pts with advanced renal 
carcinoma and tested in vivo on MTC [135]. 
Fury et al. [130] administered everolimus plus cisplatin in 30 pts with advanced solid tumors  
in a recent phase I study. Seven/30 pts had TC (5 DTC, 2 MTC). One patient with PTC completed  
14 cycles and achieved SD. The most common grade 3 AE were lymphopenia (36%), fatigue (11%)  
and hyperglycemia (11%) [130]. 
The combination of another mTOR inhibitor (Temsirolimus) plus a novel MEK inhibitor (RDEA119) 
has shown a synergistic effect in vitro [136]. 
15. Histone Deacetylase Inhibitors 
Vorinostat (suberoylanilide hydroxamic acid) is an oral histone deacetylase inhibitor, already 
approved by the USA FDA for the treatment of cutaneous T-cell lymphoma [137]. Vorinostat is able to 
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arrest TC cell growth and induce apoptosis in vitro [138]. Woyach et al. tested vorinostat (starting at 200 mg 
b.i.d. (twice daily)) in 19 pts with TC (16 DTC, 3 MTC), but no patient had a response [139]. 
Romidepsin (Depsipeptide) is a bicyclic peptide isolated from Chromobacterium violaceum. 
Depsipeptide was the first histone deacetylase inhibitor reported to be effective in pts with cutaneous  
T-cell lymphoma, peripheral T-cell lymphoma, and renal cell carcinoma [140]. It is approved by the 
USA FDA for the treatment of cutaneous T-cell lymphomas [141]. It increases the expression of Tg and 
NIS in vitro [142]. 
However, a phase II trial on romidepsin in pts with DTC was closed after the first 20 pts because of 
the lack of response and a grade 5 sudden death and a grade 4 pulmonary embolus [143]. 
16. Limits and Drug Resistance 
TKIs are generally less toxic than cytotoxic chemotherapy, but actually they cause significant side 
effects, as fatigue, hypertension, cutaneous rash, mucositis, hand-and-foot syndrome, nausea, diarrhea, 
vomiting. Also thyroid dysfunction is a well-known AE of TKI [144]; severe side effects can require the 
suspension of the therapy with TKIs. 
The efficacy of TKIs in pts with DTC has given contrasting evidence in the clinical trials, probably 
due to the drug resistance, that could arise from the activation of alternate mitogenic signals [145]. TKIs 
arrest tumor growth but do not remove tumor cells, acting as antiangiogenetic drugs [34]. 
Hence, the combination of TKIs has been recently proposed [145], though possible interaction between 
those are yet to be elucidated [146]. 
The effectiveness of the treatment could be ameliorated by the possibility to test the sensitivity of 
primary TC cells from each subject to different TKIs [147,148]. 
By human tumor cells, disease orientated in vitro drug screening has some predictive value for the 
activity of clinical responses [149,150], and could be useful to prevent the administration of inactive 
chemotherapeutics to pts [151]. 
In vitro chemosensitivity tests permit to predict in vivo effectiveness in 60% of cases [152], while  
a negative chemosensitivity test in vitro is associated with a 90% of ineffectiveness of the chemotherapy 
in vivo [150], avoiding the administration of inactive drugs to these pts. 
Till nowadays, primary TC cell cultures have been obtained from surgical biopsies performed  
for therapeutic or diagnostic procedures. Recently, our studies demonstrated that fine-needle aspiration 
(FNA) cytology overcomes this problem, thanks to the possibility to obtain primary cell culture from 
FNA samples of ATC (FNA–ANA), and opens the way to the use of FNA–ANA to test the sensitivity 
to different drugs in each patient, avoiding unnecessary surgical procedures and the administration of 
inactive therapeutics [147,152–162]. 
17. Alternative Therapeutic Strategies 
Other alternative strategies are focused on NIS, that is a plasma membrane glycoprotein sited in the 
basolateral membrane of thyrocytes, that couples sodium and iodide inward transport in favor of the 
electrochemical gradient. Iodide is therefore translocated towards the follicular lumen through the apical 
membrane by pendrine, a chloride-iodide transporter [163]. In thyroid cells, TSH stimulates NIS synthesis, 
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while thiocyanate, perchlorate, estrogens, TNF-α, TNF-β, IFN-γ, IL-1α, IL-1β, IL-6, and TGF-β1  
inhibit it [164]. 
As the expression of NIS is impaired but is still maintained, it is possible to obtain thyroid remnant 
ablation and the detection of TC relapse or metastasis by RAI. Up to 30% of persistent or metastatic TC 
loose a number of markers of thyroid cell differentiation [163], as the iodide uptake ability of follicular 
cells. Even though NIS expression can be quantitatively decreased in TC cells, the loss of the ability to 
uptake iodide seems the result of a functional impairment of NIS. It has been demonstrated by 
immunohistochemical studies that NIS may be overexpressed in some cancers [165]. Indeed, recent data 
showed that: (1) NIS localization is mostly intracellular in some TC cells [165]; (2) various NIS repressor 
have been identified (NIS-repressor, pituitary tumor transforming gene binding factor) [166,167];  
(3) the loss of NIS expression could be explained by pre-transcriptional events (as methylation of  
the NIS promoter) [168]; (4) NIS may abnormally undergo several post-transcriptional and post-translational 
modifications (for instance, glycosylation), which are able to inactive it [169]; blockers of methyltransferase 
alone [170] or in combination [171,172] are able to enhance NIS expression.  
Retinoic acids (RA) are active metabolites of vitamin A able to regulate growth and differentiation 
of many cell types. RA bind to specific nuclear receptors, the retinoic acid receptors (RAR) and the 
retinoid X receptors (RXR). Recent studies have shown RA induce in vitro re-differentiation of TC cells, 
increasing expression of NIS, and cellular (131)I uptake. RA also induce anti-proliferative effects, and 
apoptosis in TC cells. Clinical studies have demonstrated that iodide uptake may be induced after RA in 
about 20%–50% of pts with DePTC, and long-term follow-up of DePTC pts showed that RA can induce 
partial tumor regression or at least tumor growth stabilisation [173,174]. 
PPARγ agonists are another exciting field for redifferentiating therapy of DePTC [10,175,176]. 
In a clinical study 20 pts with DTC were enrolled in an open-label, phase II trial of oral rosiglitazone 
treatment. Five of 20 pts had a positive radioiodine scan after rosiglitazone treatment. By RECIST criteria, 
no patient had a complete or partial response to rosiglitazone treatment at 3 months follow-up. These findings 
suggest that rosiglitazone therapy may induce radioiodine uptake in some pts with DTC but this did not 
result in clinically significant response on long-term follow-up [177]. 
Recently, targeted NIS gene transfer, by viral and nonviral vectors, followed by radionuclide ((131)I, 
(188)Re, (211)At) therapy, has been recently suggested for the treatment of advanced or DeTC. This 
intriguing approach has prompted great interest due to the specificity as well as the low toxicity [178]. 
18. Conclusions 
Much progress has been made recently in the genetic and molecular studies of DePTC, and the set of 
known PTC driver alterations was extended (to include EIF1AX, PPM1D, and CHEK2 and some gene 
fusions). A reclassification of TCs into molecular subtypes was also proposed, that could improve the 
pathological classification of PTC, helping the management of the disease. TKIs are emerging as potentially 
effective options in the treatment of advanced TC. Sorafenib seems to be a promising therapeutic option 
in patients with advanced DePTC that are not responsive to traditional therapies. However, the efficacy 
of TKIs in pts with DTC has given contrasting evidence in the clinical trials, probably due to the drug 
resistance. Furthermore, TKIs might cause significant side effects (as fatigue, hypertension, cutaneous 
rash, mucositis, hand-and-foot syndrome, nausea, diarrhea, vomiting, thyroid dysfunctions), and severe 
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side effects can require suspension. Several studies are currently under way to evaluate the long-term 
efficacy and tolerability of TKIs in DePTC, since progression of TC can be slow. The effectiveness of 
the treatment could be ameliorated by the possibility to test the sensitivity of primary DePTC cells from 
each subject to different TKIs. In fact, disease orientated in vitro drug screening permit to predict in vivo 
effectiveness in 60% of cases, while a negative chemosensitivity test in vitro is associated with a 90% 
of ineffectiveness of the chemotherapy in vivo, avoiding the administration of inactive (potentially toxic) 
drugs to these pts. Further research is needed to determine the ideal targeted therapy, based on molecular 
characterization of the tumor and of the host factors, to obtain the best response in terms of survival and 
quality of life. 
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